各学部の研究活動
がん治療学部の研究業績(2017—2019)

先端的がん医療開発支援ユニット

研究論文

  1. Kano K, Sakamaki K, Oue N, Kimura Y, Hashimoto I, Hara K, Maezawa Y, Aoyama T, Fujikawa H, Hiroshima Y, Yamada T, Tamagawa H, Yamamoto N, Ogata T, Cho H, Ito H, Shiozawa M, Yukawa N, Yoshikawa T, Morinaga S, Rino Y, Yasui W, Masuda M, Miyagi Y, Oshima T. Impact of the ESM-1 Gene Expression on Outcomes in Stage II/III Gastric Cancer Patients Who Received Adjuvant S-1 Chemotherapy. In Vivo. 2020 Jan-Feb;34(1):461-467.
  2. Kikuchi K, Hoshino D. Sensitization of HT29 colorectal cancer cells to vemurafenib in three-dimensional collagen cultures. Cell Biol Int. 2020, In press.
  3. Oneyama M, Sakamoto N, Oue N, Kimura Y, Hiroshima Y, Hashimoto I, Hara K, Maezawa Y, Kano K, Aoyama T, Fujikawa H, Yamada T, Tamagawa H, Yamamoto N, Ogata T, Cho H, Ito H, Yukawa N, Shiozawa M, Yoshikawa T, Morinaga S, Rino Y, Masuda M, Miyagi Y, Yasui W, Oshima T. Clinical Significance of KIAA1199 as a Novel Target for Gastric Cancer Drug Therapy. Anticancer Res. 2019 Dec;39(12):6567-6573.
  4. Maezawa Y, Sakamaki K, Oue N, Kimura Y, Hashimoto I, Hara K, Kano K, Aoyama T, Hiroshima Y, Yamada T, Yamamoto N, Ogata T, Ito H, Cho H, Shiozawa M, Yoshikawa T, Morinaga S, Rino Y, Yasui W, Masuda M, Miyagi Y, Oshima T. High gamma-glutamyl hydrolase and low folylpolyglutamate synthetase expression as prognostic biomarkers in patients with locally advanced gastric cancer who were administrated postoperative adjuvant chemotherapy with S-1. J Cancer Res Clin Oncol. 2019 Nov 21.
  5. Hiroshima Y, Kasajima R, Kimura Y, Komura D, Ishikawa S, Ichikawa Y, Bouvet M, Yamamoto N, Oshima T, Morinaga S, Singh SR, Hoffman RM, Endo I, Miyagi Y. Novel targets identified by integrated cancer-stromal interactome analysis of pancreatic adenocarcinoma. Cancer Lett. 2019 Oct 24. pii: S0304-3835(19)30534-8.
  6. Igarashi K, Kawaguchi K, Murakami T, Miyake K, Kiyuna T, Miyake M, Hiroshima Y, Higuchi T, Oshiro H, Nelson SD, Dry SM, Li Y, Yamamoto N, Hayashi K, Kimura H, Miwa S, Singh SR, Tsuchiya H, Hoffman RM. Patient-derived orthotopic xenograft models of sarcoma. Cancer Lett. 2019 Oct 19. pii: S0304-3835(19)30525-7.
  7. Hashimoto I, Sakamaki K, Oue N, Kimura Y, Hiroshima Y, Hara K, Maezawa Y, Kano K, Aoyama T, Yamada T, Yamamoto N, Ogata T, Ito H, Shiozawa M, Morinaga S, Rino Y, Yasui W, Masuda M, Miyagi Y, Oshima T. Clinical Significance of PRKCI Gene Expression in Cancerous Tissue in Patients With Gastric Cancer. Anticancer Res. 2019 Oct;39(10):5715-5720.
  8. Kubo H, Hiroshima Y, Mori R, Saigusa Y, Murakami T, Yabushita Y, Sawada Y, Homma Y, Kumamoto T, Matsuyama R, Endo I. MiR-194-5p in Pancreatic Ductal Adenocarcinoma Peritoneal Washings is Associated with Peritoneal Recurrence and Overall Survival in Peritoneal Cytology-Negative Patients. Ann Surg Oncol. 2019 Dec;26(13):4506-4514.
  9. Miyake K, Higuchi T, Oshiro H, Zhang Z, Sugisawa N, Park JH, Razmjooei S, Katsuya Y, Barangi M, Li Y, Nelson SD, Murakami T, Homma Y, Hiroshima Y, Matsuyama R, Bouvet M, Chawla SP, Singh SR, Endo I, Hoffman RM. The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model. Biomed Pharmacother. 2019 Sep;117:109093.
  10. Kawaguchi D, Hiroshima Y, Kumamoto T, Mori R, Matsuyama R, Ichikawa Y, Inayama Y, Endo I. Effect of Portal Vein Ligation Plus Venous Congestion on Liver Regeneration in Rats. Ann Hepatol. 2019 Jan - Feb;18(1):89-100.
  11. Murakami T, Hiroshima Y, Matsuyama R, Homma Y, Hoffman RM, Endo I. Role of the tumor microenvironment in pancreatic cancer. Ann Gastroenterol Surg. 2019 Jan 4;3(2):130-137.
  12. Kikuchi Y, Matuyama R, Hiroshima Y, Murakami T, Bouvet M, Morioka D, Hoffman RM, Endo I. Surgical and histological boundary of the hepatic hilar plate system: basic study relevant to surgery for hilar cholangiocarcinoma regarding the "true" proximal ductal margin. J Hepatobiliary Pancreat Sci. 2019 May;26(5):159-168.
  13. Miyake K, Kiyuna T, Kawaguchi K, Higuchi T, Oshiro H, Zhang Z, Wangsiricharoen S, Razmjooei S, Li Y, Nelson SD, Murakami T, Hiroshima Y, Matsuyama R, Bouvet M, Chawla SP, Singh SR, Endo I, Hoffman RM. Regorafenib regressed a doxorubicin-resistant Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model. Cancer Chemother Pharmacol. 2019 May;83(5):809-815.
  14. Miyake K, Kiyuna T, Li S, Han Q, Tan Y, Zhao M, Oshiro H, Kawaguchi K, Higuchi T, Zhang Z, Razmjooei S, Barangi M, Wangsiricharoen S, Murakami T, Singh AS, Li Y, Nelson SD, Eilber FC, Bouvet M, Hiroshima Y, Chishima T, Matsuyama R, Singh SR, Endo I, Hoffman RM. Combining Tumor-Selective Bacterial Therapy with Salmonella typhimurium A1-R and Cancer Metabolism Targeting with Oral Recombinant Methioninase Regressed an Ewing's Sarcoma in a Patient-Derived Orthotopic Xenograft Model. Chemotherapy. 2018;63(5):278-283.
  15. Miyake K, Kiyuna T, Miyake M, Kawaguchi K, Zhang Z, Wangsiricharoen S, Razmjooei S, Oshiro H, Higuchi T, Li Y, Nelson SD, Murakami T, Hiroshima Y, Kumamoto T, Matsuyama R, Bouvet M, Singh SR, Chawla SP, Endo I, Hoffman RM. Gemcitabine combined with docetaxel precisely regressed a recurrent leiomyosarcoma peritoneal metastasis in a patient-derived orthotopic xenograft (PDOX) model. Biochem Biophys Res Commun. 2019 Feb 19;509(4):1041-1046.
  16. Miyake K, Kiyuna T, Miyake M, Zhao M, Wangsiricharoen S, Kawaguchi K, Zhang Z, Higuchi T, Razmjooei S, Li Y, Nelson SD, Russell T, Singh A, Murakami T, Hiroshima Y, Momiyama M, Matsuyama R, Chishima T, Singh SR, Chawla SP, Eilber FC, Endo I, Hoffman RM. Tumor-targeting Salmonella typhimurium A1-R overcomes partial carboplatinum-resistance of a cancer of unknown primary (CUP). Tissue Cell. 2018 Oct;54:144-149.
  17. Miyake K, Kawaguchi K, Miyake M, Zhao M, Kiyuna T, Igarashi K, Zhang Z, Murakami T, Li Y, Nelson SD, Bouvet M, Elliott I, Russell TA, Singh AS, Hiroshima Y, Momiyama M, Matsuyama R, Chishima T, Singh SR, Endo I, Eilber FC, Hoffman RM. Tumor-targeting Salmonella typhimurium A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations. Heliyon. 2018 Jun 6;4(6):e00643.
  18. Sato K, Mori R, Hiroshima Y, Oba MS, Matsuyama R, Bouvet M, Hoffman RM, Endo I. RT-PCR of peritoneal washings predicts peritoneal pancreatic cancer recurrence. J Surg Res. 2018 Jun;226:122-130.
  19. Miyake K, Kiyuna T, Miyake M, Kawaguchi K, Yoon SN, Zhang Z, Igarashi K, Razmjooei S, Wangsiricharoen S, Murakami T, Li Y, Nelson SD, Russell TA, Singh AS, Hiroshima Y, Momiyama M, Matsuyama R, Chishima T, Singh SR, Endo I, Eilber FC, Hoffman RM. Patient-derived orthotopic xenograft models for cancer of unknown primary precisely distinguish chemotherapy, and tumor-targeting S. typhimurium A1-R is superior to first-line chemotherapy. Signal Transduct Target Ther. 2018 Apr 27;3:12.
  20. Miyake K, Kawaguchi K, Kiyuna T, Miyake M, Igarashi K, Zhang Z, Murakami T, Li Y, Nelson SD, Elliott I, Russell T, Singh A, Hiroshima Y, Momiyama M, Matsuyama R, Chisima T, Endo I, Eilber FC, Hoffman RM. Regorafenib regresses an imatinib-resistant recurrent gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 in a patient-derived orthotopic xenograft (PDOX) nude mouse model. Cell Cycle. 2018 Jan 15:1-21.
  21. Kikuchi Y, Hiroshima Y, Matsuo K, Murakami T, Kawaguchi D, Kasahara K, Tanaka K. Impact of associating liver partition and portal vein occlusion for staged hepatectomy on tumor growth in a mouse model of liver metastasis. Eur J Surg Oncol. 2018 Jan;44(1):130-138.
  22. Miyake K, Murakami T, Kiyuna T, Igarashi K, Kawaguchi K, Li Y, Singh AS, Dry SM, Eckardt MA, Hiroshima Y, Momiyama M, Matsuyama R, Chishima T, Endo I, Eilber FC, Hoffman RM. Eribulin regresses a doxorubicin-resistant Ewing's sarcoma with a FUS-ERG fusion and CDKN2A-deletion in a patient-derived orthotopic xenograft (PDOX) nude mouse model. J Cell Biochem. 2018 Jan;119(1):967-972.
  23. Murakami T, Hiroshima Y, Zhang Y, Zhao M, Kiyuna T, Hwang HK, Miyake K, Homma Y, Mori R, Matsuyama R, Chishima T, Ichikawa Y, Tanaka K, Bouvet M, Endo I, Hoffman RM. Tumor-Targeting Salmonella typhimurium A1-R Promotes Tumoricidal CD8+ T Cell Tumor Infiltration and Arrests Growth and Metastasis in a Syngeneic Pancreatic-Cancer Orthotopic Mouse Model. J Cell Biochem. 2018 Jan;119(1):634-639.
  24. Kikuchi Y, Hiroshima Y, Matsuo K, Murakami T, Kawaguchi D, Endo I, Yamazaki K, Ishida Y, Tanaka K. Remnant Liver Tumor Growth Activity During Treatment Associating Liver Partition and Portal Vein Occlusion for Staged Hepatectomy (ALPPS). J Gastrointest Surg. 2017 Nov;21(11):1851-1858.
  25. Miyake K, Murakami T, Kiyuna T, Igarashi K, Kawaguchi K, Miyake M, Li Y, Nelson SD, Dry SM, Bouvet M, Elliott IA, Russell TA, Singh AS, Eckardt MA, Hiroshima Y, Momiyama M, Matsuyama R, Chishima T, Endo I, Eilber FC, Hoffman RM. The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a FUS-ERG fusion and CDKN2A deletion: Direction for third-line patient therapy. Oncotarget. 2017 Sep 8;8(61):103129-103136.
  26. Matsuo K, Hiroshima Y, Yamazaki K, Kasahara K, Kikuchi Y, Kawaguchi D, Murakami T, Ishida Y, Tanaka K. Immaturity of Bile Canalicular-Ductule Networks in the Future Liver Remnant While Associating Liver Partition and Portal Vein Occlusion for Staged Hepatectomy (ALPPS). Ann Surg Oncol. 2017 Sep;24(9):2456-2464.
  27. Murakami T, Homma Y, Matsuyama R, Mori R, Miyake K, Tanaka Y, Den K, Nagashima Y, Nakazawa M, Hiroshima Y, Ueda M, Tanaka K, Hoffman RM, Bouvet M, Endo I. Neoadjuvant chemoradiotherapy of pancreatic cancer induces a favorable immunogenic tumor microenvironment associated with increased major histocompatibility complex class I-related chain A/B expression. J Surg Oncol. 2017 Sep;116(3):416-426.
  28. Murakami T, Kiyuna T, Kawaguchi K, Igarashi K, Singh AS, Hiroshima Y, Zhang Y, Zhao M, Miyake K, Nelson SD, Dry SM, Li Y, DeLong JC, Lwin TM, Chishima T, Tanaka K, Bouvet M, Endo I, Eilber FC, Hoffman RM. The irony of highly-effective bacterial therapy of a patient-derived orthotopic xenograft (PDOX) model of Ewing's sarcoma, which was blocked by Ewing himself 80 years ago. Cell Cycle. 2017 Jun 3;16(11):1046-1052.
  29. Kawaguchi D, Hiroshima Y, Kikuchi Y, Matsuo K, Tanaka K. Associating Liver Partition and Portal Vein Occlusion, Including Venous Congestion, Induction in Rats. Anticancer Res. 2017 Jun;37(6):2919-2925.
  30. Murakami T, Li S, Han Q, Tan Y, Kiyuna T, Igarashi K, Kawaguchi K, Hwang HK, Miyake K, Singh AS, Nelson SD, Dry SM, Li Y, Hiroshima Y, Lwin TM, DeLong JC, Chishima T, Tanaka K, Bouvet M, Endo I, Eilber FC, Hoffman RM. Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. Oncotarget. 2017 May 30;8(22):35630-35638.
  31. Murakami T, Hiroshima Y, Miyake K, Hwang HK, Kiyuna T, DeLong JC, Lwin TM, Matsuyama R, Mori R, Kumamoto T, Chishima T, Tanaka K, Ichikawa Y, Bouvet M, Endo I, Hoffman RM. Color-coded intravital imaging demonstrates a transforming growth factor-β (TGF-β) antagonist selectively targets stromal cells in a human pancreatic-cancer orthotopic mouse model. Cell Cycle. 2017 May 19;16(10):1008-1014.
  32. Kawaguchi K, Murakami T, Suetsugu A, Kiyuna T, Igarashi K, Hiroshima Y, Zhao M, Zhang Y, Bouvet M, Clary BM, Unno M, Hoffman RM. High-efficacy targeting of colon-cancer liver metastasis with Salmonella typhimurium A1-R via intra-portal-vein injection in orthotopic nude-mouse models. Oncotarget. 2017 Mar 21;8(12):19065-19073.
  33. Tanaka K, Kikuchi Y, Kawaguchi D, Murakami T, Hiroshima Y, Matsuo K. Modified ALPPS Procedures Avoiding Division of Portal Pedicles. Ann Surg. 2017 Feb;265(2):e14-e20.
  34. Murakami T, Igarashi K, Kawaguchi K, Kiyuna T, Zhang Y, Zhao M, Hiroshima Y, Nelson SD, Dry SM, Li Y, Yanagawa J, Russell T, Federman N, Singh A, Elliott I, Matsuyama R, Chishima T, Tanaka K, Endo I, Eilber FC, Hoffman RM. Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug. Oncotarget. 2017 Jan 31;8(5):8035-8042.

総説等

  1. 大津敬、北河徳彦、後藤裕明、田中祐吉、宮城洋平. 非上皮性腫瘍(GIST,小児がん)のPDX作製法.実験医学別冊・患者由来がんモデルを用いたがん研究実践ガイド:pp 195- 204, 2019.
  2. Murakami T, Hiroshima Y, Miyake K, Kiyuna T, Endo I, Zhao M, Hoffman RM. Efficacy of Tumor-Targeting Salmonella typhimurium A1-R against Malignancies in Patient-Derived Orthotopic Xenograft (PDOX) Murine Models. Cells. 2019 Jun 16;8(6). pii: E599. Review.
  3. Kikuchi K, Kozuka-Hata H, Oyama M, Seiki M, Koshikawa N. Identification of Proteolytic Cleavage Sites of EphA2 by Membrane Type 1 Matrix Metalloproteinase on the Surface of Cancer Cells. Methods Mol Biol. 2018;1731:29-37.

がん分子標的探索ユニット

研究論文

  1. Rieko Matsuura, Hiroyuki Kaji, Azusa Tomioka, Takashi Sato, Hisashi Narimatsu, Yasuhiro Moriwaki, Hidemi Misawa, Kohzoh Imai, and Shoutaro Tsuji. Identification of mesothelioma-specific sialylated epitope recognized with monoclonal antibody SKM9-2 in a mucin-like membrane protein HEG1. Scientific Reports 8:14251, 2018.
  2. Tsutomu Shinohara, Shoutaro Tsuji, Yoshio Okano, Hisanori Machida, Nobuo Hatakeyama, Fumitaka Ogushi. Elevated Levels of Intelectin-1, a Pathogen-binding Lectin, in the BAL Fluid of Patients with Chronic Eosinophilic Pneumonia and Hypersensitivity Pneumonitis. Internal Medicine 57:3507–3514, 2018.
  3. Yasuhiro Moriwaki, Yuho Ohno, Tomohiro Ishii, Yuki Takamura, Yuko Kita, Kazuhiko Watabe, Kazunori Sango, Shoutaro Tsuji, and Hidemi Misawa. SIMPLE binds specifically to PI4P through SIMPLE-like domain and participates in protein trafficking in the trans-Golgi network and/or recycling endosome. PLoS ONE 13:e0199829, 2018.
  4. Shoutaro Tsuji, Kota Washimi, Taihei Kageyama, Makiko Yamashita, Mitsuyo Yoshihara, Rieko Matsuura, Tomoyuki Yokose, Yoichi Kameda, Hiroyuki Hayashi, Takao Morohoshi, Yukio Tsuura, Toshikazu Yusa, Takashi Sato, Akira Togayachi, Hisashi Narimatsu, Toshinori Nagasaki, Kotaro Nakamoto, Yasuhiro Moriwaki, Hidemi Misawa, Kenzo Hiroshima, Yohei Miyagi, and Kohzoh Imai. HEG1 is a novel mucin-like membrane protein that serves as a diagnostic and therapeutic target for malignant mesothelioma. Scientific Reports 7:45768, 2017.

総説等

  1. 辻 祥太郎, 今井 浩三. 新しい悪性中皮腫マーカー・シアル化HEG1による精密・早期診断の開発と臨床への展開. 医学のあゆみ(医歯薬出版株式会社)271(9):810–816, 2019.
  2. 辻 祥太郎. 中皮腫の糖鎖修飾がん抗原を標的とする抗体医薬の開発. Drug Delivery System 34(4):284–290, 2019.
  3. 辻 祥太郎, 今井 浩三. 12章 DDSを利用した抗体医薬開発の展望. ドラッグデリバリーシステム(株式会社シーエムシー出版), 2018.